Prelude Therapeutics, Inc. ( (PRLD) ) has released its Q4 earnings. Here is a breakdown of the information Prelude Therapeutics, Inc. presented to its investors.
Prelude Therapeutics, Inc., a clinical-stage precision oncology company, focuses on developing innovative cancer treatments with a pipeline that includes first-in-class SMARCA2 degraders and other precision oncology targets.
In its latest earnings report, Prelude Therapeutics highlighted significant progress in its clinical development pipeline, particularly with its SMARCA2 degrader programs, while also reporting financial results for the full year 2024.
Key financial metrics revealed that Prelude ended 2024 with $133.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second quarter of 2026. The company reported a net loss of $127.2 million for the year, with increased R&D expenses due to expanded clinical trials. Prelude’s clinical advancements include nearing completion of dose escalation for PRT3789 and ongoing trials for PRT7732, with promising interim data expected in late 2025.
The company also announced strategic developments, such as a new CFO appointment and a collaboration with Merck for a Phase 2 trial of PRT3789 combined with KEYTRUDA®. Prelude’s focus remains on advancing its SMARCA2 degrader programs and exploring partnerships for other projects like PRT2527.
Looking ahead, Prelude Therapeutics is poised to continue its mission to deliver precision oncology medicines, with anticipated updates on its discovery pipeline and ongoing clinical trials throughout 2025.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com